Start of ATX101 Clinical Development

AUROBAC announces the successful dosing of the first healthy volunteers in its Phase 1 clinical trial evaluating its sepsis drug candidate, ATX101 (NCT07107802).

ATX101 is a first-in-class treatment, addressing shock, organ failure and mortality in sepsis, a life-threatening condition for which current treatments are limited and often insufficient.

This milestone is the result of a strong and productive collaboration with Boehringer Ingelheim, reflecting our shared commitment to developing innovative therapies to tackle urgent unmet medical in patients in critical care settings.

Know more